BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22236988)

  • 1. B-cell receptor inhibitors in chronic lymphocytic leukemia.
    Flinn IW
    Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Danilov AV
    Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cell receptor inhibition as a target for CLL therapy.
    Jeyakumar D; O'Brien S
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):2-14. PubMed ID: 27742069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
    Spaargaren M; de Rooij MF; Kater AP; Eldering E
    Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
    Foluso O; Glick A; Stender M; Jaiyesimi I
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):63-9. PubMed ID: 26775273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Targeted treatment of chronic lymphocytic leukaemia].
    Niemann CU
    Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
    Burger JA
    Curr Hematol Malig Rep; 2012 Mar; 7(1):26-33. PubMed ID: 22105489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
    Brown JR
    Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
    Choi MY; Kipps TJ
    Cancer J; 2012; 18(5):404-10. PubMed ID: 23006944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibition of B cell receptor signaling: a first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas].
    Mráz M; Doubek M; Mayer J
    Klin Onkol; 2013; 26(3):179-85. PubMed ID: 23763320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
    Pospisilova S; Sutton LA; Malcikova J; Tausch E; Rossi D; Montserrat E; Moreno C; Stamatopoulos K; Gaidano G; Rosenquist R; Ghia P;
    Haematologica; 2016 Mar; 101(3):263-5. PubMed ID: 26928246
    [No Abstract]   [Full Text] [Related]  

  • 13. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
    Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V
    Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
    Mato A; Jauhari S; Schuster SJ
    Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
    Burger JA; Okkenhaug K
    Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapies Improve Outlook for Chronic Lymphocytic Leukemia.
    Brower V
    J Natl Cancer Inst; 2015 Dec; 107(12):djv396. PubMed ID: 26657100
    [No Abstract]   [Full Text] [Related]  

  • 17. Ibrutinib treatment of CLL: the cancer fights back.
    Young RM; Staudt LM
    Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Kinase Inhibitors.
    Lamanna N
    Oncology (Williston Park); 2015 Jun; 29(6):443, 445. PubMed ID: 26091680
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
    Dias AL; Jain D
    Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):265-71. PubMed ID: 24433470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib-Induced Lymphocytosis: Cytological Features.
    Quintela A; Sujobert P; Callet-Bauchu E; Salles G; Baseggio L
    Acta Haematol; 2017; 137(1):55-57. PubMed ID: 27960168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.